Biotech Values

[jq1234]

PLX's PRX112: I thought it was underappreciated. From press release:

Presence of an enzyme was detected in patients' blood circulation and the enzyme demonstrated biological activity. In addition, some of the patients who suffered from thrombocytopenia and had low platelet counts demonstrated a meaningful improvement in platelet count. Accordingly, the trial has been extended to enroll and evaluate additional Gaucher patients with low platelet counts. The amended study is expected to conclude during the fourth quarter of 2013. Additional data from the phase I study will be presented at the 10th Annual WORLD Symposium, February 10-13, 2014 in San Diego, CA.

It showed the oral delivery has activity after 4 doses (1 single dose plus 3 consecutive daily dose). I am looking forward to the data presentation in Feb.